In Silico Identification of Structure Requirement for Novel Thiazole and Oxazole Derivatives as Potent Fructose 1,6-Bisphosphatase Inhibitors

Fructose 1,6-bisphosphatase (FBPase) has been identified as a drug discovery target for lowering glucose in type 2 diabetes mellitus. In this study, a large series of 105 FBPase inhibitors were studied using a combinational method by 3D-QSAR, molecular docking and molecular dynamics simulations for a further improvement in potency. The optimal 3D models exhibit high statistical significance of the results, especially for the CoMFA results with rncv2, q2 values of 0.986, 0.514 for internal validation, and rpred2, rm2 statistics of 0.902, 0.828 statistics for external validation. Graphic representation of the results, as contoured 3D coefficient plots, also provides a clue to the reasonable modification of molecules. (1) Substituents with a proper length and size at the C5 position of the thiazole core are required to enhance the potency; (2) A small and electron-withdrawing group at the C2 position linked to the thiazole core is likely to help increase the FBPase inhibition; (3) Substituent groups as hydrogen bond acceptors at the C2 position of the furan ring are favored. In addition, the agreement between 3D-QSAR, molecular docking and molecular dynamics simulation proves the rationality of the developed models. These results, we hope, may be helpful in designing novel and potential FBPase inhibitors.

[1]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[2]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[3]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[4]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[5]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[6]  H. Lebovitz,et al.  Characterization and Significance of Sulfonylurea Receptors , 1990, Diabetes Care.

[7]  T. Claus,et al.  Hepatic gluconeogenesis/glycolysis: regulation and structure/function relationships of substrate cycle enzymes. , 1991, Annual review of nutrition.

[8]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[9]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[10]  M. Erion,et al.  The allosteric site of human liver fructose-1,6-bisphosphatase. Analysis of six AMP site mutants based on the crystal structure. , 1995, The Journal of biological chemistry.

[11]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[12]  R. Klein.  Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes , 1995, Diabetes Care.

[13]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[14]  P. Rorsman,et al.  Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. , 1998, Diabetes.

[15]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[16]  E. Ferrannini,et al.  Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.

[17]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[18]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[19]  M. Mansour,et al.  Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. , 2002, Journal of medicinal chemistry.

[20]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[21]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[22]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[23]  Alexander Golbraikh,et al.  Rational selection of training and test sets for the development of validated QSAR models , 2003, J. Comput. Aided Mol. Des..

[24]  M. Mansour,et al.  3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. , 2003, Bioorganic & medicinal chemistry letters.

[25]  Hongmao Sun,et al.  Prediction of Chemical Carcinogenicity from Molecular Structure , 2004, J. Chem. Inf. Model..

[26]  Hongmao Sun,et al.  A Universal Molecular Descriptor System for Prediction of LogP, LogS, LogBB, and Absorption , 2004, J. Chem. Inf. Model..

[27]  Alexander Golbraikh,et al.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2004, Molecular Diversity.

[28]  Tao Jiang,et al.  MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Ling Yang,et al.  Classification of Substrates and Inhibitors of P-Glycoprotein Using Unsupervised Machine Learning Approach , 2005, J. Chem. Inf. Model..

[30]  Ling Yang,et al.  An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network , 2005, J. Comput. Aided Mol. Des..

[31]  C. Abad-Zapatero,et al.  Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase. , 2006, Bioorganic & medicinal chemistry letters.

[32]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[33]  W. Lipscomb,et al.  Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. , 2007, Journal of the American Chemical Society.

[34]  W. Lipscomb,et al.  Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity. , 2007, Journal of the American Chemical Society.

[35]  P. Roy,et al.  On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .

[36]  Chang-Guo Zhan,et al.  Combined 3D-QSAR Modeling and Molecular Docking Study on Indolinone Derivatives as Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase-1 , 2008, J. Chem. Inf. Model..

[37]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[38]  Yonghua Wang,et al.  Understanding the Aquatic Toxicity of Pesticide: Structure‐Activity Relationship and Molecular Descriptors to Distinguish the Ratings of Toxicity , 2009 .

[39]  M. Erion,et al.  Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics. , 2009, Journal of medicinal chemistry.

[40]  K. Roy,et al.  Predictive QSAR modeling of CCR5 antagonist piperidine derivatives using chemometric tools. , 2009, Journal of enzyme inhibition and medicinal chemistry.

[41]  Y. Li,et al.  Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. , 2010, Current medicinal chemistry.

[42]  Wei Yang,et al.  Mechanism of MicroRNA-Target Interaction: Molecular Dynamics Simulations and Thermodynamics Analysis , 2010, PLoS Comput. Biol..

[43]  M. Erion,et al.  Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics. , 2010, Journal of medicinal chemistry.

[44]  M. Erion,et al.  Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. , 2011, Journal of medicinal chemistry.

[45]  Zhiqiang Wu,et al.  Molecular modeling studies on phosphonic acid-containing thiazole derivatives: design for fructose-1,6-bisphosphatase inhibitors , 2012, Journal of Molecular Modeling.

[46]  M. Erion,et al.  Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity , 2011 .

[47]  Xue Xu,et al.  Dynamic communication between androgen and coactivator: Mutually induced conformational perturbations in androgen receptor ligand‐binding domain , 2011, Proteins.